Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. (DOSE.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dose.cn · pe ratio · data through Feb 28, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Rapid Dose Therapeutics Corp. (DOSE.CN) measures how much investors pay for each dollar of the company's trailing earnings. DOSE.CN's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$0.03.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-02-28
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Rapid Dose Therapeutics Corp.You DOSE.CN | $13M | N/A | — | -$0.03 |
 BriaCell Therapeutics Corp. BCT.TO | $8M | N/A | — | -$62.95 |
 Britannia Life Sciences Inc. BLAB.CN | $14M | 1.65x | — | $0.05 |
 Gemina Laboratories Ltd. GLAB.CN | $5M | N/A | — | -$0.06 |
 Greenway Greenhouse Cannabis Corporation GWAY.CN | $21M | N/A | — | -$0.02 |
 Hemostemix Inc. HEM.V | $10M | N/A | — | -$0.03 |
 Pharmala Biotech Holdings Inc. MDMA.CN | $15M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-02-28Latest FY2025 | — | $-0.04 | — | |
2024-02-29 FY2024 | — | $-0.04 | — | |
2023-02-28 FY2023 | — | $-0.04 | — | |
2022-02-28 FY2022 | — | $-0.08 | — | |
2021-02-28 FY2021 | — | $-0.02 | — | |
2020-02-29 FY2020 | — | $-0.10 | — | |
2019-02-28 FY2019 | — | $-0.18 | — | |
2017-09-30 FY2017 | — | $-0.00 | — | |
2016-09-30 FY2016 | — | $-0.06 | — | |
2015-09-30 FY2015 | — | $-0.11 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Rapid Dose Therapeutics Corp. (DOSE.CN) measures how much investors pay for each dollar of the company's trailing earnings. DOSE.CN's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$0.03.
Frequently asked questions
DOSE.CN pe ratio · 6 questionsDOSE.CN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.10 and TTM EPS of -$0.03. Data sourced from Financial Modeling Prep via DOSE.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Rapid Dose Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08